The Medicinal Materials Research Center is developing novel pharmaceutical materials for treating refractory diseases.
Our research focuses on: i) the development of cancer immunotherapeutics, ii) tumor immune microenvironment reprogramming technology, and iii) precision cancer immunotherapy technology. Additionally, we aim to realize precision medicine (prevention, diagnosis, and treatment) for refractory diseases through the establishment of patient-specific treatment technologies based on 'theragnosis' and immune fusion technologies.